Myriad Genetics
MYGN
MYGN
201 hedge funds and large institutions have $2.3B invested in Myriad Genetics in 2021 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 71 increasing their positions, 61 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
1.16% more ownership
Funds ownership: 96.82% → 97.98% (+1.2%)
2% more capital invested
Capital invested by funds: $2.25B → $2.3B (+$53.5M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
201
Holding in Top 10
1
Calls
$4.34M
Puts
$2.98M
Top Buyers
| 1 | +$34.1M | |
| 2 | +$26.9M | |
| 3 | +$15.7M | |
| 4 |
BlackRock
New York
|
+$11.4M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$11.3M |
Top Sellers
| 1 | -$30.3M | |
| 2 | -$12.8M | |
| 3 | -$8.31M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$7.99M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$6.59M |